Primary Investigator: Dr Gary Mitchell
We hypothesise that brain origin ccfDNA measured by PCR has both high sensitivity and high specificity for the detection of mild traumatic brain injury (m-TBI).
Aim – Perform a feasibility pilot study on brain-origin ccfDNA to test sensitivity and specificity in patients with m-TBI.
The specific aims are to measure brain-origin ccfDNA in 100 adult ED patients stratified into four groups (acute stroke, seizure, acute orthopaedic injuries, m-TBI) and:
- Compare the concentrations of brain-origin ccfDNA between the groups
- Determine the sensitivity and specificity of brain-origin ccfDNA in detecting m-TBI
- Determine the rate of recruitment, retention and reasons for withdrawal of participants
- Evaluate the practicalities and logistics of collecting, storing & handling biological samples in the ED
- Evaluate the acceptability of the study to ED staff.
If ccfDNA is specific and sensitive for patients with m-TBI, we will perform a prospective multi-centre observational trial comparing the biomarker in patients who have suffered a m-TBI with or without concurrent orthopaedic injuries and compare with functional imaging and other tested biomarkers (GFAP and UCH-L1).